MSA Declares Fourth Quarter Dividend
Get Alerts MSA Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 0.3%
Revenue Growth %: +4.7%
Join SI Premium – FREE
PITTSBURGH, Nov. 10, 2015 /PRNewswire/ -- The Board of Directors of MSA Safety Incorporated (NYSE: MSA) today declared a fourth quarter dividend of 32 cents per share on common stock, payable December 10, 2015 to shareholders of record on November 23, 2015.
The Board also declared a dividend of 56-1/4 cents per share on preferred stock, payable December 1, 2015 to shareholders of record on November 23, 2015.
About MSAEstablished in 1914, MSA Safety Incorporated is the global leader in the development, manufacture and supply of safety products that protect people and facility infrastructures. Many MSA products integrate a combination of electronics, mechanical systems and advanced materials to protect users against hazardous or life-threatening situations. The company's comprehensive line of products is used by workers around the world in a broad range of markets, including the oil, gas and petrochemical industry, the fire service, the construction industry, mining and the military. The company's core products include self-contained breathing apparatus, fixed gas and flame detection systems, portable gas detection instruments, industrial head protection, fire and rescue helmets and fall protection devices. With 2014 revenues of $1.1 billion, MSA employs approximately 4.600 people worldwide. The company is headquartered north of Pittsburgh in Cranberry Township, Pa., and has manufacturing operations in the United States, Europe, Asia and Latin America. With more than 40 international locations, MSA realizes approximately half of its revenue from outside North America. For more information visit MSA's website at www.MSAsafety.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/msa-declares-fourth-quarter-dividend-300175836.html
SOURCE MSA
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual
- Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
- SAMARITAN'S PURSE EBOLA TREATMENT CENTERS OPEN IN THE EPICENTER OF THE DEADLY OUTBREAK
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share